Baker Brothers Advisors - Q2 2023 holdings

$17.3 Billion is the total value of Baker Brothers Advisors's 107 reported holdings in Q2 2023. The portfolio turnover from Q1 2023 to Q2 2023 was 17.1% .

 Value Shares↓ Weighting
SGEN SellSeagen Inc.$8,574,894,019
-9.7%
44,554,162
-5.0%
49.62%
-4.0%
INCY BuyIncyte Corporation$2,252,083,986
-13.9%
36,178,056
+0.0%
13.03%
-8.4%
BGNE  BeiGene, Ltd.sponsored adr$2,080,564,335
-17.3%
11,668,8970.0%12.04%
-12.0%
ACAD BuyACADIA Pharmaceuticals Inc.$1,026,607,457
+30.1%
42,864,612
+2.2%
5.94%
+38.4%
MDGL  Madrigal Pharmaceuticals, Inc.$356,921,103
-4.6%
1,545,1130.0%2.07%
+1.4%
BMRN  BioMarin Pharmaceutical Inc.$330,272,297
-10.9%
3,810,2480.0%1.91%
-5.2%
IMCR  Immunocore Holdings plcads$151,143,031
+21.3%
2,520,7310.0%0.88%
+29.1%
NewInvitae Corporationnote 1.5% 4/1/2028$135,000,000300,000,000
+100.0%
0.78%
KOD  Kodiak Sciences Inc.$119,442,381
+11.3%
17,310,4900.0%0.69%
+18.3%
AKRO  Akero Therapeutics, Inc.$110,579,569
+22.0%
2,368,3780.0%0.64%
+29.8%
ARGX  argenx SEsponsored adr$109,186,367
+4.6%
280,1590.0%0.63%
+11.3%
RYTM  Rhythm Pharmaceuticals, Inc.$107,156,423
-7.6%
6,498,2670.0%0.62%
-1.7%
REPL  Replimune Group, Inc.$106,307,662
+31.5%
4,578,2800.0%0.62%
+39.8%
ABCL BuyAbCellera Biologics Inc.$106,268,163
+34.9%
16,450,180
+57.4%
0.62%
+43.4%
KYMR BuyKymera Therapeutics, Inc.$100,589,067
+17.9%
4,375,340
+51.9%
0.58%
+25.4%
BuyRoivant Sciences Ltd.$95,040,207
+169.6%
9,428,592
+97.4%
0.55%
+186.5%
BCRX  BioCryst Pharmaceuticals, Inc.$89,484,159
-15.6%
12,710,8180.0%0.52%
-10.2%
SWTX BuySpringWorks Therapeutics, Inc.$78,655,962
+11.0%
2,999,846
+8.9%
0.46%
+17.9%
 Entrada Therapeutics, Inc.$73,668,500
+4.4%
4,865,8190.0%0.43%
+10.9%
RVMD  Revolution Medicines, Inc.$71,997,438
+23.5%
2,691,4930.0%0.42%
+31.5%
IMTX BuyImmatics N.V.$65,095,017
+81.9%
5,640,816
+8.7%
0.38%
+93.3%
KDNY  Chinook Therapeutics, Inc.$55,908,861
+66.0%
1,455,2020.0%0.32%
+77.0%
MRTX  Mirati Therapeutics, Inc.$50,935,496
-2.8%
1,409,7840.0%0.30%
+3.5%
 DICE Therapeutics, Inc.$48,122,618
+62.2%
1,035,7860.0%0.28%
+72.7%
BMEA  Biomea Fusion, Inc.$46,291,431
-29.2%
2,108,9490.0%0.27%
-24.7%
PRLD  Prelude Therapeutics Inc.$45,557,208
-21.1%
10,123,8240.0%0.26%
-15.9%
DNLI BuyDenali Therapeutics Inc.$42,946,552
+71.2%
1,455,322
+33.7%
0.25%
+83.1%
CERS  Cerus Corporation$39,526,193
-17.2%
16,067,5580.0%0.23%
-11.9%
KNSA BuyKiniksa Pharmaceuticals, Ltd.$39,558,844
+31.3%
2,809,577
+0.4%
0.23%
+39.6%
NRIX  Nurix Therapeutics, Inc.$38,782,429
+12.5%
3,882,1250.0%0.22%
+19.1%
RARE BuyUltragenyx Pharmaceutical Inc.$36,122,512
+91.3%
783,059
+66.3%
0.21%
+102.9%
AVTE  Aerovate Therapeutics, Inc.$33,673,665
-15.0%
1,963,4790.0%0.20%
-9.3%
IGMS BuyIGM Biosciences, Inc.$29,141,048
-32.8%
3,157,210
+0.0%
0.17%
-28.4%
XENE  Xenon Pharmaceuticals Inc.$28,938,102
+7.6%
751,6390.0%0.17%
+14.4%
IMGN NewImmunoGen, Inc.$28,684,2301,520,097
+100.0%
0.17%
DBVT  DBV Technologies S.A.sponsored adr$27,767,102
+12.4%
14,614,2640.0%0.16%
+20.1%
VERV  Verve Therapeutics, Inc.$26,559,938
+30.0%
1,416,5300.0%0.15%
+38.7%
 2seventy bio, Inc.$25,274,963
-0.8%
2,497,5260.0%0.15%
+5.0%
IDYA BuyIDEAYA Biosciences, Inc.$24,959,891
+118.3%
1,062,123
+27.5%
0.14%
+132.3%
STOK BuyStoke Therapeutics, Inc.$22,644,430
+28.5%
2,130,238
+0.7%
0.13%
+36.5%
BCYC  Bicycle Therapeutics plcsponsored ads$21,534,133
+20.0%
843,8140.0%0.12%
+27.6%
GLUE BuyMonte Rosa Therapeutics, Inc.$20,714,064
+608.9%
3,023,951
+706.2%
0.12%
+650.0%
CABA BuyCabaletta Bio, Inc.$20,578,540
+85.1%
1,594,000
+18.6%
0.12%
+98.3%
KRYS SellKrystal Biotech, Inc.$19,950,252
-17.7%
169,934
-43.9%
0.12%
-12.9%
SMMT  Summit Therapeutics Inc.$15,824,810
+43.4%
6,304,7050.0%0.09%
+53.3%
ANAB  AnaptysBio, Inc.$15,782,294
-6.5%
775,9240.0%0.09%
-1.1%
 Prime Medicine, Inc.$15,067,027
+19.1%
1,028,4660.0%0.09%
+26.1%
PACB  Pacific Biosciences of California, Inc.$14,999,501
+14.9%
1,127,7820.0%0.09%
+22.5%
RLAY BuyRelay Therapeutics, Inc.$14,571,070
+211.5%
1,160,117
+308.5%
0.08%
+236.0%
SBTX  ARS Pharmaceuticals, Inc.$13,443,222
+2.9%
2,006,4510.0%0.08%
+9.9%
SANA  Sana Biotechnology, Inc.$11,920,000
+82.3%
2,000,0000.0%0.07%
+91.7%
DAWN NewDay One Biopharmaceuticals, Inc.$11,940,0001,000,000
+100.0%
0.07%
COGT NewCogent Biosciences, Inc.$11,598,464979,600
+100.0%
0.07%
PNT  POINT Biopharma Global Inc.$10,592,073
+24.6%
1,169,1030.0%0.06%
+32.6%
ADAP BuyAdaptimmune Therapeutics plcsponsored adr$10,146,586
-5.3%
10,969,282
+11.6%
0.06%
+1.7%
NVTA  Invitae Corporation$10,035,648
-16.3%
8,881,1040.0%0.06%
-10.8%
NewVerastem, Inc.$9,943,4481,336,485
+100.0%
0.06%
GERN  Geron Corporation$9,826,529
+47.9%
3,061,2240.0%0.06%
+58.3%
HRTX  Heron Therapeutics, Inc.$9,432,746
-23.2%
8,131,6780.0%0.06%
-17.9%
ATHA BuyAthira Pharma, Inc.$9,303,731
+58.3%
3,153,807
+34.2%
0.05%
+68.8%
RNA SellAvidity Biosciences, Inc.$8,865,912
-42.5%
799,451
-20.4%
0.05%
-39.3%
BLUE  bluebird bio, Inc.$8,224,062
+3.5%
2,499,7150.0%0.05%
+11.6%
FATE  Fate Therapeutics, Inc.$7,957,373
-16.5%
1,671,7170.0%0.05%
-11.5%
ALLO  Allogene Therapeutics, Inc.$7,837,198
+0.6%
1,576,9010.0%0.04%
+7.1%
OPT  Opthea Limitedsponsored ads$7,535,895
-29.1%
2,691,3910.0%0.04%
-24.1%
INSM  Insmed Incorporated$7,237,300
+23.8%
343,0000.0%0.04%
+31.2%
 TScan Therapeutics, Inc.$6,961,980
+19.0%
2,784,7920.0%0.04%
+25.0%
 Aadi Bioscience, Inc.$6,771,108
-5.5%
989,9280.0%0.04%0.0%
ALEC  Alector, Inc.$5,798,755
-2.9%
964,8510.0%0.03%
+6.2%
SellSera Prognostics, Inc.$5,856,648
-14.5%
1,777,435
-0.6%
0.03%
-8.1%
CMPX  Compass Therapeutics, Inc.$4,953,263
-2.8%
1,557,6300.0%0.03%
+3.6%
NTRA  Natera, Inc.$4,866,000
-12.4%
100,0000.0%0.03%
-6.7%
MGNX  MacroGenics, Inc.$4,775,298
-25.4%
892,5790.0%0.03%
-20.0%
MREO NewMereo BioPharma Group PLCsponsored ads$4,692,5723,554,979
+100.0%
0.03%
ARAV  Aravive, Inc.$4,109,142
-37.0%
3,261,2240.0%0.02%
-31.4%
HOOK BuyHOOKIPA Pharma Inc.$3,894,471
+52.2%
4,425,535
+27.3%
0.02%
+64.3%
AFMD  Affimed N.V.$3,946,224
-19.8%
6,596,8300.0%0.02%
-14.8%
EWTX  Edgewise Therapeutics, Inc.$3,875,000
+16.2%
500,0000.0%0.02%
+22.2%
GRCL NewGracell Biotechnologies Inc.sponsored ads$3,810,0001,000,000
+100.0%
0.02%
IPSC  Century Therapeutics, Inc.$3,631,914
-8.9%
1,149,3400.0%0.02%
-4.5%
MRSN SellMersana Therapeutics, Inc.$3,573,318
-53.9%
1,086,115
-42.4%
0.02%
-50.0%
NewLeap Therapeutics, Inc.$3,668,9081,172,175
+100.0%
0.02%
NewTalis Biomedical Corporation$3,659,9217,624,835
+100.0%
0.02%
BCEL  Atreca, Inc.$3,462,105
-14.0%
3,532,7600.0%0.02%
-9.1%
DSGN SellDesign Therapeutics, Inc.$3,150,000
-12.9%
500,000
-20.2%
0.02%
-10.0%
NLTX  Neoleukin Therapeutics, Inc.$3,172,044
+18.6%
3,821,7400.0%0.02%
+20.0%
XNCR  Xencor, Inc.$3,074,481
-10.5%
123,1270.0%0.02%
-5.3%
TIL  Instil Bio, Inc.$2,905,858
-16.6%
5,273,7890.0%0.02%
-10.5%
 Tango Therapeutics, Inc.$2,490,000
-15.9%
750,0000.0%0.01%
-12.5%
VERA SellVera Therapeutics, Inc.cl a$2,350,747
-9.1%
146,464
-56.1%
0.01%0.0%
ACHL SellAchilles Therapeutics plcsponsored ads$2,417,017
-2.6%
2,557,149
-1.3%
0.01%
+7.7%
PCVX  Vaxcyte, Inc.$2,441,317
+33.2%
48,8850.0%0.01%
+40.0%
PRAX  Praxis Precision Medicines, Inc.$2,161,902
+42.2%
1,879,9150.0%0.01%
+62.5%
ALGS  Aligos Therapeutics, Inc.$2,016,184
+11.1%
2,076,4000.0%0.01%
+20.0%
PMVP  PMV Pharmaceuticals, Inc.$2,015,870
+31.2%
322,0240.0%0.01%
+50.0%
ITOS  iTeos Therapeutics, Inc.$1,990,581
-2.7%
150,3460.0%0.01%
+9.1%
VOR  Vor Biopharma Inc.$1,958,590
-42.6%
633,8480.0%0.01%
-42.1%
BuyKala Pharmaceuticals, Inc.$1,695,548
+46.7%
116,213
+51.3%
0.01%
+66.7%
ISR NewPerspective Therapeutics, Inc.$1,549,2832,319,286
+100.0%
0.01%
AGLE  Aeglea BioTherapeutics, Inc.$1,536,253
+55.3%
3,410,1060.0%0.01%
+80.0%
FGEN SellFibroGen, Inc.$642,827
-98.7%
238,084
-91.0%
0.00%
-98.5%
NKTX SellNkarta, Inc.$594,211
-58.2%
271,329
-32.2%
0.00%
-62.5%
TARA  Protara Therapeutics, Inc.$477,214
-23.6%
199,6710.0%0.00%0.0%
VINC SellVincerx Pharma, Inc.$293,253
+16.8%
225,579
-6.5%
0.00%
+100.0%
GTH  Genetron Holdings Limitedads$423,480
-11.4%
455,3060.0%0.00%
-33.3%
FHTX  Foghorn Therapeutics Inc.$316,990
+13.5%
45,0270.0%0.00%0.0%
 Surrozen, Inc.w exp 8/11/2026$46,000
-44.8%
833,3330.0%0.00%
ExitBellicum Pharmaceuticals, Inc.$0-249,123
-100.0%
0.00%
TCRR ExitTCR2 Therapeutics Inc.$0-753,064
-100.0%
-0.01%
VERU ExitVeru Inc.$0-1,609,579
-100.0%
-0.01%
ATRA ExitAtara Biotherapeutics, Inc.$0-744,186
-100.0%
-0.01%
LPTX ExitLeap Therapeutics, Inc.$0-7,425,570
-100.0%
-0.01%
TLIS ExitTalis Biomedical Corporation$0-7,624,835
-100.0%
-0.02%
VSTM ExitVerastem, Inc.$0-25,521,447
-100.0%
-0.06%
BPMC ExitBlueprint Medicines Corporation$0-333,665
-100.0%
-0.08%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2023-08-14
Signatures

The EDGAR filing(s) were signed by:

About Baker Brothers Advisors

Baker Brothers Advisors is a well-known investment management firm that specializes in the healthcare sector. The firm was founded in 2000 by brothers Julian and Felix Baker, who are both highly respected in the industry. Julian Baker is the CEO of the firm, while Felix Baker serves as a managing partner.

Baker Brothers Advisors has a reputation for investing in innovative healthcare companies that have the potential to make a significant impact on the industry. The firm has a long-term investment approach and is known for taking large positions in companies that it believes in. Some of the firm's most successful investments include companies such as Pharmacyclics, which was acquired by AbbVie for $21 billion, and Ariad Pharmaceuticals, which was acquired by Takeda for $5.2 billion.

The firm's investment strategy is led by its Chief Investment Officer, Dr. Robert Duggan, who has a background in both medicine and finance. Dr. Duggan is known for his ability to identify promising healthcare companies and for his willingness to take risks on early-stage companies.

Overall, Baker Brothers Advisors is a highly respected investment management firm that has a proven track record of success in the healthcare sector. While the firm's investment approach may not be suitable for all investors, those who are interested in the healthcare sector may want to consider Baker Brothers Advisors as a potential investment opportunity.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
Incyte Corporation42Q3 202337.6%
ACADIA Pharmaceuticals Inc.42Q3 202310.9%
Biomarin Pharmaceuticals Inc.42Q3 20235.9%
BioCryst Pharmaceuticals, Inc.42Q3 20231.7%
Cerus Corporation42Q3 20230.9%
Insmed Incorporated42Q3 20230.4%
Mirati Therapeutics, Inc.41Q3 20231.8%
Bluebird Bio Inc.41Q3 20230.3%
Heron Therapeutics, Inc.39Q3 20231.5%
ChemoCentryx, Inc.37Q3 20220.6%

View Baker Brothers Advisors's complete holdings history.

Latest significant ownerships (13-D/G)
Baker Brothers Advisors Q2 2023 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
Neoleukin Therapeutics, Inc.August 17, 20239,469,83820.0%
Mereo Biopharma Group plcAugust 10, 202314,604,3912.2%
Verastem, Inc.August 10, 2023? ?
TScan Therapeutics, Inc.June 02, 20232,793,9386.5%
ACADIA PHARMACEUTICALS INCMay 24, 202343,084,28026.5%
INCYTE CORPMarch 15, 202336,280,96716.3%
Seagen Inc.March 13, 202346,985,65625.1%
Talis Biomedical CorpMarch 10, 202337,569,14066.2%
Aeglea BioTherapeutics, Inc.February 14, 20236,384,0139.9%
Merus N.V.February 14, 2023? ?

View Baker Brothers Advisors's complete significant-ownership history.

Latest filings
TypeFiled
32024-04-18
SC 13D2024-04-18
32024-04-01
42024-04-01
42024-04-01
42024-04-01
SC 13D2024-04-01
42024-03-28
SC 13D/A2024-03-28
42024-03-25

View Baker Brothers Advisors's complete filings history.

Compare quarters

Export Baker Brothers Advisors's holdings